Skip to main content
Equibles
FHTX logo

FHTX · Foghorn Therapeutics Inc. · Metrics

Track FHTX — free

Use FHTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research FHTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.00 -0.01 (-0.50%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$118.77M
Shares
59.39M
Volume · Oct 23 486.83K Avg daily vol (3M) 689.14K

FHTX metrics

81 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.00
Market cap
$118.77M

Price action

20 metrics
Price change (1W)
+8.1%
Price change (30D)
-42.9%
Price change (3M)
-58.8%
Price change (6M)
-62.3%
Price change (YTD)
-63.0%
Price change (1Y)
-48.7%
Trailing year
Price change (5Y)
-84.3%
52-week high
$7.07
52-week low
$1.85
Change from 52-week high
-71.7%
Change from 52-week low
+8.1%
Annualized volatility
83.5%
Annualized volatility (3M)
96.7%
Beta
1.6
RSI (14D)
24.6
Price vs SMA 50
-50.9%
Price vs SMA 200
-58.4%
Avg volume (3M)
689,139
Relative volume
0.7
Average dollar volume
$2.42M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
59.39M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.4×
reciprocal yield 72.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
3.2×
reciprocal yield 30.9%
P / book
—
FCF yield
-71.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-54.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
7.1×
reciprocal yield 14.1%
EV / revenue historical average (5Y)
61.9×
reciprocal yield 1.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2021-08-10

Profitability

9 metrics
Gross margin
—
Operating margin
-198.0%
Trailing 12 months
Net margin
-175.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$72.76M
Net income (TTM)
−$64.58M
Trailing 12 months
Diluted EPS (TTM)
$-0.99
FCF margin
-229.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.55
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.11
EBITDA per diluted share (TTM)
$-1.08
Net income per diluted share (TTM)
$-0.98
Operating cash flow per diluted share (TTM)
$-1.27
Free cash flow per diluted share (TTM)
$-1.27
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$1.19
Stock compensation per diluted share (TTM)
$0.15
Book value per share
$-1.92

Growth

11 metrics
Revenue growth YoY
+112.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$36.74M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+12.1%
Year over year · more shares
Revenue CAGR (3Y)
+17.1%
Revenue CAGR (5Y)
+135.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-31.8%
Debt / equity
—
Current ratio
3.4
EBITDA (TTM)
−$70.71M
Free cash flow (TTM)
−$84.29M
Quick ratio
3.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$68.08M
Latest balance sheet
Cash & equivalents
$68.08M
Total assets
$203.39M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$84.24M
Capital expenditures (TTM)
$50,000
R&D (TTM)
$78.83M
SG&A (TTM)
—
Stock compensation (TTM)
$9.91M
R&D / revenue
214.6%
Stock compensation / revenue
27.0%

Ownership (13F)

9 metrics
13F filers
102
13F filer change QoQ
-3
Institutional ownership
75.6%
Conviction holders (share of 13F filers)
2.0%
Crowding (high-turnover and private-fund holders)
33.7%
Private-fund adviser ownership
33.6%
Active holders' share change QoQ
+0.1%
Holder tenure
15.3
Price vs estimated holder cost
-57.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
7.4%

Short interest

3 metrics
Short interest
3.6%
Latest settlement · 4.3 days to cover
Days to cover
4.3d
Short-squeeze score
45 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1822462 CUSIP 344174107 13F (30d) 9 filings 9 filers Visit website Investor relations